Hemostemix Files for Ethics Approval of its Study of Vascular Dementia
Calgary, Alberta--(Newsfile Corp. - October 9, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is...
Neuroscience
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
Event to be held October 14th at 4 p.m. ESTBETHESDA, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc....
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era...
An Era Where Meditation Becomes a Quantifiable Achievement — Japan’s First “Quantified Meditation Challenge”
TOKYO, Oct. 7, 2025 /PRNewswire/ -- Meditation entered a new era as the World Meditation League (WML), and All Here...
Boosting clinical trial success in Alzheimer’s, Parkinson’s and other neurodegenerative diseases, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how biomarkers and digital tools are improving clinical trials in neurodegenerative diseases. Attendees will understand the...
Albert Einstein College of Medicine Awarded $18 Million NIH Grant to Improve Treatment for Serious Mental Illness
New Predictive Platform Will Use Digital Technology and AI to Assist Clinician Decision-Making BRONX, N.Y., Oct. 6, 2025 /PRNewswire/ -- Serious...
Clario and the University of Oxford’s NeuroMetrology Lab Advance Parkinson’s Disease Research with the Opal® Wearable Sensor System
Clario partners with the University of Oxford's NeuroMetrology Lab to transform Parkinson's disease research with the Opal® wearable sensor system. Partnership...
Neuropsychiatry Clinical Trials: Evolving with Portable EEG and Digital Endpoints, Upcoming Webinar Hosted by Xtalks
In this free webinar, hear from CNS thought-leaders on the transformative power of objective measures of brain function in neuropsychiatry clinical...
Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off
The Company expects to reestablish and announce a new record date as soon as possibleALAMEDA, Calif., Oct. 03, 2025 (GLOBE...
The magnetic math of breast health
COLD SPRING HARBOR, N.Y., Oct. 2, 2025 /PRNewswire/ -- Branching isn't just for trees. This biological process occurs in animal development,...
Linus Health Showcases Role of Digital Tools and Biomarkers in Early Brain Health Detection at AAFP’s FMX 2025
BOSTON, Oct. 1, 2025 /PRNewswire/ -- Linus Health, an AI-driven brain health company pioneering early detection of cognitive impairment and personalized...
Transformed by His Promises Offers a 12-Week Journey to Emotional and Behavioral Freedom
Released in time for World Mental Health Day, "Transformed by His Promises" equips readers with clinically informed strategies and structured...
Spring Health Convenes AI in Mental Health Safety & Ethics Council to Set Industry Standards for Responsible AI
NEW YORK, Oct. 1, 2025 /PRNewswire/ -- Today, a coalition of leaders from academia, healthcare, technology, and employee benefits announced the...
DataJoint Closes $4.9M Seed Funding to Revolutionize Data Management and AI in Academic and Life Sciences /Pharma
BARCELONA, Spain and SALT LAKE CITY and AUSTIN, Texas, Sept. 30, 2025 /PRNewswire/ -- DataJoint, a leading computational database and...
The ADDF’s Diagnostics Accelerator Unveils SpeechDx Dataset and New Partnership to Catalyze Breakthroughs in Speech-Based Biomarkers
The gold-standard dataset will power a new generation of AI tools to forecast Alzheimer's risk, track progression, and guide interventions...
Neurophet Publishes Clinical Validation Results of ‘Neurophet AQUA’ in Annals Academy of Medicine Singapore
- Clinical study conducted at the Dementia Research Centre, Nanyang Technological University, Singapore, involving Southeast Asian participants - Expert level accuracy,...
Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial
Publication title: “Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of...
Reunion Neuroscience Announces First Patient Dosed in REKINDLE Phase 2 Clinical Trial of RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses
-- AjD Represents an Area of Significant Unmet Need; No U.S. Food and Drug Administration (FDA)-Approved Therapies Available -- --...
Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer’s Detection
VANCOUVER, British Columbia, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:...
Cognision and SOMNOmedics Forge Strategic Partnership to Advance Sleep Biomarkers in Pharmaceutical Clinical Trials
LOUISVILLE, Ky., Sept. 24, 2025 /PRNewswire/ -- Cognision, a leader in high-performance neurophysiological biomarker solutions and services, has announced a...